In Depth 13 Jun 2023
Abeta-targeting antibodies pave the way for Alzheimer’s disease vaccines
By Dr. Andrea Pfeifer, CEO of AC Immune SA The clinical success we’ve recently seen with two monoclonal antibodies that target the protein amyloid beta (Abeta) has provided hope for patients, a significant boost to the sector but also a strong validation of the “amyloid hypothesis”: removing Abeta plaques is a valid therapeutic strategy for […]